Alaunos Therapeutics, Inc. TCRT
Set alert
1.95 USD +0.06 +3.17%
At close
1.87 -0.08 -4.10%
Pre-market · Nov 2, 8:35 AM ET
1.68 Day range 2.04
0.72 52-week range 4.50
- YTD
- -39.63%
- 1 year
- -28.31%
- Open
- 1.84
- Prev close
- 1.89
- Mkt cap
- 6.71M
- Vol
- 772.29K
- Avg vol
- 7.53M
- EPS
- -1.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.68
- High
- 2.04
- Forward P/E
- -3.25
- Beta
- -0.50
- Short ratio
- 10.12
- Inst. own
- 12.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 2, 2024
- 50-d avg
- 2.18
- 200-d avg
- 6.90
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -0.7; estimate 0; surprise —%
Signals (83)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| RSI: Overbought | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| RSI: Overbought | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| RSI: Oversold | Sep 8, 2026 | 1 month ago |
| RSI: Oversold | Aug 27, 2026 | 2 months ago |
| RSI: Oversold | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
| SMA: Bearish | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Mar 25, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| RSI: Overbought | Mar 6, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 27, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 9, 2026 | 9 months ago |
| SMA: Bullish | Jan 8, 2026 | 9 months ago |
| SMA: Bearish | Dec 31, 2025 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 26, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 30, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 28, 2025 | 1 year ago |
| RSI: Oversold | Aug 20, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 30, 2025 | 1 year ago |
| MACD: Sell Signal | May 15, 2025 | 1 year ago |
| MACD: Buy Signal | May 7, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 17, 2025 | 1 year ago |
| SMA: Bullish | Apr 1, 2025 | 1 year ago |
| RSI: Overbought | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 14, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 6, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
| RSI: Overbought | Nov 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 3.12M
- Enterprise value
- 883.62K
- Trailing P/E
- 0.00
- Forward P/E
- -3.25
- PEG ratio
- 0.00
- Price / sales
- 446.15
- Price / book
- 0.50
- EPS (TTM)
- -315.39
- Beta
- -0.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.00K
- Revenue growth
- 0.00%
- Free cash flow
- -11.83M
- Total cash
- 2.46M
- Total debt
- 0
- Return on equity
- -150.50%
- Shares outstanding
- 1.60M
- Short % of float
- 10.11%
- 50-day average
- 2.18
- 200-day average
- 6.90
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Apr 2, 2024
Expected Apr 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TCRT Revenue — quarterly 0
TCRT Net income — quarterly -952.00K
TCRT EPS — quarterly -0.41
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.70 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.71 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.10 | — | — |
| Apr 2, 2024 | Dec 1, 2023 | -0.60 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -4.50 | -6.00 | -1.50 | -33.33% |
| Aug 14, 2023 | Jun 1, 2023 | -6.00 | -6.00 | 0.00 | 0.00% |
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alaunos.com
News
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on TCRT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAFFA RAFFAELE | Officer | Stock Award(Grant) | May 16, 2021 | 280,645 |
| BOWDEN CHRISTOPHER J | Director | Stock Award(Grant) | Jun 21, 2022 | 44,167 |
| BOYLE KEVIN S. SR | Chief Executive Officer | Sale | Aug 31, 2023 | 798,236 |
| DE GROOT ELEANOR M | Officer | Sale | Dec 21, 2021 | 237,106 |
| HAGEN HEIDI | Director | Purchase | Sep 1, 2021 | 145,889 |
| HUANG JAMES Z | Director | Stock Award(Grant) | Jun 21, 2022 | 188,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MSD Partners, L.P. | 6.31% | 101,010 | 197.01K | Sep 29, 2024 |
| Vanguard Group Inc | 2.83% | 45,348 | 88.45K | Sep 29, 2024 |
| Blackrock Inc. | 1.39% | 22,233 | 43.36K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 16,333 | 31.86K | Sep 29, 2024 |
| Morgan Stanley | 0.08% | 1,337 | 2.61K | Sep 29, 2024 |
| UBS Group AG | 0.06% | 1,028 | 2.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.60% | 25,676 | 50.08K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.28% | 20,471 | 39.93K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 8,924 | 17.41K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 2,376 | 4.63K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 2,082 | 4.06K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | 0.08% | 1,271 | 2.48K | Jul 30, 2024 |